MEDSHealthcare · Medical Distribution

MEDS Stock Forecast: DataMeds AI, Inc. Price Predictions for 2026-2027

Last close, 11 Aug 2026

$1.39

−13.13% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 10 Aug 2026 — in the weakest quartile.

Market cap

$5.7M

Ticker Nerd rank

16 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

−56.2%

−54.7%

YTD

−93.0%

−96.2%

From 52W high

−98.4%

From 52W low

0.0%

$87

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MEDS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DataMeds AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Growth

Revisions

Momentum

Volatility

Value

Issuance

Quality

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Wall Street

MEDS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
1 June 2023	EF Hutton	Assumes	Buy	$1.25
16 May 2023	EF Hutton	Maintains	Buy	$1.70 → $1.25
28 Mar 2023	Maxim Group	Maintains	Buy	$2.50 → $1.75
9 Dec 2021	EF Hutton	Initiates	Buy	$4.50
3 Dec 2020	National Securities	Initiates	Buy	—
3 Dec 2020	National Securities Corporation	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDS appears on the weeks it earns a place.

Estimates

MEDS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

DataMeds AI, Inc. (MEDS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: 0.4×
Price / book: −0.3×
EV / EBITDA: −0.6×

Growth & margins

Revenue growth (YoY): −85.6%
Earnings growth (YoY): 2304.5%
Gross margin: 10.9%
Operating margin: −385.7%
Net margin: −27.5%

Returns & dividend

Return on equity: 813.6%
Return on assets: −79.2%
Dividend yield: 306.1%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MEDS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution

Company	Market cap	TKN rank
MEDSDataMeds AI, Inc.	$5.7M	16
SNYRSynergy CHC Corp.	$2.4M	48
COSMCosmos Health, Inc.	$13.4M	25
NXGLNexGel, Inc.*	$4.1M	25
VVOSVivos Therapeutics, Inc.*	$4.3M	11
RNAZTransCode Therapeutics, Inc.*	$4.1M	28
ELABPMGC Holdings, Inc.*	$4.1M	3

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

The rank is the raw material. Whether the rules would actually own DataMeds AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MEDS news & analysis

DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division

Accesswire · 10 Aug 2026neutral

DataMeds AI, Inc. (NASDAQ:MEDS) announced that it has completed name changes of its pharmacy and pharmacy-hub subsidiaries, now known as Corexa Pharmacy, LLC and Corexa Tech & Hub, LLC, respectively. Both subsidiaries now operate under the Company's newly renamed pharmacy-focused division, Corexa Health, LLC.

Why it matters — The reorganization signals how DataMeds AI is structuring its pharmacy operations under a unified Corexa Health division, which may matter to investors tracking the Company's corporate framework.

DataMeds AI Reiterates 50:1 Dream Bowl Meme Coin Token to Common Shares Dividend Ratio with an August 7, 2026 Record Date

Accesswire · 6 Aug 2026neutral

DataMeds AI, Inc. (NASDAQ:MEDS) reiterated the August 7, 2026 record date for its 50:1 Dream Bowl Meme Coin token to common shares dividend ratio, and noted the official platform for the tokens is Biconomy.

Why it matters — MEDS watchers would care because the announcement provides a definitive record date and reiterates the terms for the company's token-to-share dividend.

DataMeds AI to be Featured In-Person on Fox Business' Claman Countdown to Introduce "Health Lives Here"

Accesswire · 5 Aug 2026positive

DataMeds AI announced that Interim Co-CEO Gerald Commissiong will appear on Fox Business' "Claman Countdown" alongside a NFL Hall of Famer on August 5, 2026, to introduce the "Health Lives Here" initiative, a partnership with NFL Alumni Health aimed at improving rural healthcare access through independent pharmacies, wearables, and the company's Einstein AI platform.

Why it matters — MEDS watchers would care because this national TV appearance with a high-profile partner signals increased visibility for DataMeds AI's rural health initiative and potential to expand its Einstein AI and independent pharmacy network into a new consumer-facing healthcare channel.

DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)

Accesswire · 31 July 2026positive

DataMeds AI announced that its wholly-owned online pharmacy, Corexa Pharmacy, has begun direct-to-consumer distribution of Tollovid and Galactovid, two products from Tollo Health targeting acute viral infection and Long COVID markets.

Why it matters — This launch expands Corexa Pharmacy's product offerings into the viral infection and Long COVID space, giving MEDS watchers a view of how the company is broadening its DTC pharmacy business.

DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

Accesswire · 29 July 2026positive

DataMeds AI and Datavault AI amended their agreement to expand the PharmacyChain blockchain technology license beyond pharmaceutical distribution to include all unencumbered commercial healthcare, healthspan, and wellness applications of Datavault AI's intellectual property.

Why it matters — DataMeds watchers would note that the expanded license broadens the company's access to healthcare data monetization and blockchain technology across additional commercial healthcare segments.

FAQ

Frequently asked questions about MEDS stock

How does Ticker Nerd's model rank MEDS?

As at 10 Aug 2026, DataMeds AI, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

What is the MEDS stock forecast for 2030?

No analyst covering DataMeds AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDS are extrapolating price history, which says nothing about the business.

How has MEDS stock performed over the past year?

DataMeds AI, Inc. returned -96.2% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DataMeds AI, Inc. do?

Scienture Holdings Inc. is a diversified company engaged in various sectors, including technology and industrial operations.

What is the latest news on MEDS?

The most recent item we track (Accesswire, 10 Aug 2026): "DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division". DataMeds AI, Inc. (NASDAQ:MEDS) announced that it has completed name changes of its pharmacy and pharmacy-hub subsidiaries, now known as Corexa Pharmacy, LLC and Corexa Tech & Hub, LLC, respectively. Both subsidiaries now operate under the Company's newly renamed pharmacy-focused division, Corexa Health, LLC.

Company

About DataMeds AI, Inc.

Scienture Holdings Inc. is a diversified company engaged in various sectors, including technology and industrial operations. The primary function of Scienture Holdings Inc. is to invest in and manage a portfolio of businesses that offer innovative solutions and cutting-edge products. With interests spanning multiple industries, the company focuses on fostering growth and operational efficiency in its subsidiary companies. Among its notable features is its strategic investment in technology-driven enterprises that aim to enhance productivity and streamline operations across different market segments. Scienture Holdings Inc. plays a significant role in advancing technological progress while ensuring sustainable development and competitive advantage for its businesses. By maintaining a diverse investment strategy, the company seeks to mitigate risks and maximize potential returns in the dynamic financial markets. Furthermore, Scienture Holdings Inc. contributes to the broader economic landscape by aligning its business operations with emerging market demands and evolving consumer needs, making it a crucial player in the sectors it serves.

CEO Mr. Prashant Patel M.Sc., R.Ph. · 8 employees · United States · https://datamedsai.com